WUXI BIOLOGICS CAYMAN INC USD0000025 144A REG S ISIN KYG9700
COM · CUSIP G97008109
1
institutional holders
+0 vs Q1 2020
3.1m
shares reported held*
$56.5mreported value*
0 new
1 added
0 reduced
0 sold out
net bought ≈ $16.5m (+900.5k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $18.30.
Trends to Q2 2020
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2019 | 1 |
| Q1 2020 | 1 |
| Q2 2020 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2020 | 1 | 0 |
| Q2 2020 | 1 | 0 |
Biggest buyers
| GILDER GAGNON HOWE & CO LLC | Added | +900.5k |
Biggest sellers
| None |
Holders, Q2 2020
| Manager | Shares | Change |
|---|---|---|
| GILDER GAGNON HOWE & CO LLC 0.44% of their portfolio | 3.1m $56.5m | Added +900.5k |